Filing Details
- Accession Number:
- 0001062993-24-001164
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-22 18:59:20
- Reporting Period:
- 2024-01-19
- Accepted Time:
- 2024-01-22 18:59:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1042074 | Cymabay Therapeutics Inc. | CBAY | Pharmaceutical Preparations (2834) | 943103561 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1588862 | Charles Mcwherter | C/O Cymabay Therapeutics, Inc. 7575 Gateway Blvd., Suite 110 Newark CA 94560 | President Of R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-19 | 2,250 | $1.06 | 17,250 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-19 | 2,250 | $23.67 | 15,000 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-01-19 | 2,778 | $1.72 | 17,778 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-19 | 2,778 | $23.66 | 15,000 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-01-19 | 1,916 | $1.82 | 16,916 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-19 | 1,916 | $23.66 | 15,000 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-01-19 | 8,334 | $10.00 | 23,334 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-19 | 8,334 | $23.68 | 15,000 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-01-19 | 3,125 | $11.69 | 18,125 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-19 | 3,125 | $23.68 | 15,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2024-01-19 | 2,250 | $0.00 | 2,250 | $1.06 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2024-01-19 | 2,778 | $0.00 | 2,778 | $1.72 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2024-01-19 | 1,916 | $0.00 | 1,916 | $1.82 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2024-01-19 | 8,334 | $0.00 | 8,334 | $10.00 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2024-01-19 | 3,125 | $0.00 | 3,125 | $11.69 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 51,750 | 2026-01-25 | No | 4 | M | Direct | |
| 97,222 | 2027-01-18 | No | 4 | M | Direct | |
| 44,084 | 2026-07-24 | No | 4 | M | Direct | |
| 91,666 | 2025-01-06 | No | 4 | M | Direct | |
| 146,875 | 2028-01-23 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 29, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.48 to $24.20, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $24.305, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option vested as to 1/4 of the underlying shares on the first anniversary of the grant date and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
- The option vested as to 1/2 of the underlying shares on December 30, 2016 and the remaining 1/2 of the underlying shares vested on January 4, 2017.
- The option vested as to 1/4 of the underlying shares on January 1, 2019 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
Billionaire Hedge Funds
